🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. Everolimus

    Novartis Pharmaceuticals

    Advanced NET of GI Origin

    phase 3 small molecule completed

    1 trial

  2. Fingolimod

    Novartis Pharmaceuticals

    Multiple Sclerosis (MS)

    phase 3 small molecule active

    1 trial

  3. Flucelvax Tetra - suspension for injection in pre-filled syringe Influenza vaccine (surface antigen, inactivated, prepared in cell cultures), PNEUMOVAX solution injectable en flacon Vaccin pneumococcique polyosidique, Pneumovax 23 oldatos injekció előretöltött fecskendőben Pneumococcus-poliszacharid vakcina, BOOSTRIX, suspension injectable en seringue préremplie Vaccin diphtérique, tétanique et coquelucheux (acellulaire multicomposé), (adsorbé, à teneur réduite en antigènes), Pneumovax 23 oldatos injekció e

    Novartis Pharmaceuticals

    Relapsing multiple sclerosis (RMS)

    phase 3 small molecule active

    1 trial

  4. Fulvestrant

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  5. Fulvestrant

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  6. GOSERELIN, RIBOCICLIB, ANASTROZOLE, LETROZOLE

    Novartis Pharmaceuticals

    hormone receptor (HR)-positive, HER2-negative, early breast cancer (EBC).

    phase 3 small molecule active

    1 trial

  7. Gilenya 0.5 mg hard capsules, Gilenya 0.25 mg hard capsules

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  8. Glycopyrronium bromide

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    1 trial

  9. INCLISIRAN, -

    Novartis Pharmaceuticals

    Familial hypercholsterolemia

    phase 3 small molecule active

    1 trial

  10. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  11. INCLISIRAN, KJX839, Placebo to KJX839 (Inclisiran) 0 mg/1.5 mL Solution for injection in vial

    Novartis Pharmaceuticals

    homozygous familial hypercholesterolemia

    phase 3 small molecule active

    1 trial

  12. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  13. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical hemolytic uremic syndrome

    phase 3 small molecule active

    1 trial

  14. IPTACOPAN

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome (aHUS)

    phase 3 small molecule active

    1 trial

  15. IPTACOPAN HYDROCHLORIDE

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  16. IPTACOPAN, LNP023

    Novartis Pharmaceuticals

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 3 small molecule active

    1 trial

  17. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia (ITP)

    phase 3 mab active

    1 trial

  18. Ianalumab

    Novartis Pharmaceuticals

    Primary Immune Thrombocytopenia

    phase 3 mab active

    2 trials

  19. Inclisiran

    Novartis Pharmaceuticals

    Familial Hypercholesterolemia - Heterozygous

    phase 3 small molecule completed

    1 trial

  20. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease (COPD)

    phase 3 small molecule completed

    1 trial

  21. Indacaterol 150 μg

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule completed

    2 trials

  22. Investigators choice of SoC

    Novartis Pharmaceuticals

    Prostate Cancer

    phase 3 small molecule active

    1 trial

  23. Iptacopan

    Novartis Pharmaceuticals

    Atypical Hemolytic Uremic Syndrome

    phase 3 small molecule completed

    1 trial

  24. JDQ443

    Novartis Pharmaceuticals

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources